• Publications
  • Influence
Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys
Abstract Increased distractibility is associated with both Alzheimer’s disease and attention deficit disorder. The present study examined the effects of (–)-nicotine and the novel central nicotinic
Chronic, low-level exposure to diisopropylfluorophosphate causes protracted impairment of spatial navigation learning
Chronic, low-level OP exposure produces protracted impairment of working memory after drug withdrawal that is not associated with continued suppression of AChE activity, but may, however, be associated with a decreased rate of A cholinesterase inhibitor organophosphate recovery in the hippocampus, relative to the cortex.
Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017
Improvements in DMTS performance in aged monkeys may have particular implications for neurodegenerative conditions such as AD, whereas positive results in the younger monkeys indicate that RS 17017 (or similar compounds) may have additional potential in the therapeutics of memory disorders not necessarily associated with advanced age.
Relative levels of cytoprotection produced by analogs of choline and the role of α7‐nicotinic acetylcholine receptors
It is confirmed here that choline offers a significant degree of protection against the cytotoxicity induced by growth factor deprivation in differentiated PC‐12 cells, consistent with the possibility that the choline structure may serve as a template for the development of novel agents with both α7‐nicotinic agonist activity and potential neuroprotective ability.
Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418
Transdermal delivery of ABT-418 in non-aged monkeys demonstrated prolonged performance enhancement compared with IM injection to at least 24 h after patch administration, consistent with the ability of ABt-418 to improve DMTS performance in both young and aged monkeys.
The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys
The acute effect of dimebolin on components of working memory in non‐human primates, young adult (11–17 years old) and aged and aged rhesus macaques is examined.
Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
The therapeutic agents currently used to treat schizophrenia effectively improve psychotic symptoms; however, they are limited by adverse effects and poor efficacy when negative symptoms of the